# Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)

> **NCT03319316** · PHASE2 · WITHDRAWN · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC**

## Conditions studied

- Squamous Non-small Cell Lung Cancer
- Non-Squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT03319316
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-11-01
- **Primary completion:** 2021-11
- **Final completion:** 2022-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Interest withdrawn
- **Last updated:** 2022-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03319316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03319316, "Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03319316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*